ORBACTIV
Total Payments
$2.4M
Transactions
10,296
Doctors
4,008
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $643,333 | 49 | 2 |
| 2018 | $12,218 | 145 | 136 |
| 2017 | $1.8M | 10,102 | 3,924 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 119 | 48.4% |
| Honoraria | $717,975 | 400 | 29.8% |
| Food and Beverage | $285,153 | 9,107 | 11.8% |
| Travel and Lodging | $141,086 | 537 | 5.9% |
| Consulting Fee | $26,971 | 21 | 1.1% |
| Education | $25,842 | 91 | 1.1% |
| Grant | $25,000 | 1 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $21,450 | 20 | 0.9% |
Payments by Type
General
$1.2M
10,177 transactions
Research
$1.2M
119 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ML-ORI-102 | Melinta Therapeutics, Inc. | $576,221 | 0 |
| A RETROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE UTILIZATION, OUTCOMES, AND ADVERSE EVENTS IN PARTICIPANTS TREATED WITH ORBACTIV ORITAVANCIN FOR INFECTIONS CAUSED BY GRAM POSITIVE BACTERIA IN A REAL WORLD SETTING | The Medicines Company | $143,855 | 0 |
| Double-Blind, Randomized Study to Evaluate the Safety of either a Single IZOD-mg Intravenous IV Dose of OrbactivTM oritavancin and Placebo or two N Doses of OrbactivTM in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection ABSSSI | The Medicines Company | $129,596 | 0 |
| Comparative Efficacy of Oritavancin in the Rabbit Model of Treatment of Experimental Mcthicillin Resistant Staphylococcus aureus Endocarditis | The Medicines Company | $101,000 | 0 |
| A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin lnfusions in Healthy Subjects | The Medicines Company | $61,337 | 0 |
| TMC-ORI-10-01 | Melinta Therapeutics, Inc. | $59,514 | 0 |
| OPEN-LABEL, DOSE-FINDING, PHARMACOKINETICS, SAFETY AND TOLERABILITY STUDY OF ORITAVANCIN IN PEDIATRIC PATIENTS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTIONS | The Medicines Company | $37,293 | 1 |
| Orbactiv Pre-Clinical US | The Medicines Company | $27,100 | 0 |
| In Vitro Compressive Strength Testing of Oritavancin Loaded Polymethylmethacrylate PMMA Beads | The Medicines Company | $10,190 | 0 |
| Activity of oritavancin versus daptomycin or linezolid alone and in combination with gentamicin, rifampin or ceftriaxone against multi-drug resistant Enterococcus jaecium in in vitro time-kill assays and in vivo survival assays using Galleriamellonella larvae. | The Medicines Company | $8,847 | 0 |
| TMC-ORI-11-01 | Melinta Therapeutics, Inc. | $7,578 | 0 |
| An Open label, Dose finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Subjects Less Than I8 Years of Age with Suspected or Confirmed Bacterial Infections | The Medicines Company | $2,973 | 0 |
| An Open label, Dose-finding, Pharmacokinerics, Safety, and Tolerability Sludy of Oriiavancin Single Dose Injusion in Pediatric Subjects Less Than 18 Years of Age with Suspected or Confirmed Baclerial Infections | The Medicines Company | $750.00 | 0 |
Top Doctors Receiving Payments for ORBACTIV — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Infectious Disease | El Paso, TX | $9,533 | 29 |
| , D.O | Infectious Disease | Rancho Mirage, CA | $9,521 | 10 |
| , D. O | Internal Medicine | Temple, TX | $9,031 | 27 |
| , MD | Infectious Disease | Cincinnati, OH | $8,979 | 14 |
| , M.D | Internal Medicine | Chicago, IL | $8,869 | 16 |
| , MD | Infectious Disease | Vernal, UT | $8,452 | 19 |
| David Sperling | — | Signal Hill, CA | $8,251 | 19 |
| , MD | Infectious Disease | Huntsville, AL | $7,715 | 15 |
| , M.D | Infectious Disease | Victoria, TX | $7,634 | 17 |
| , MD | Emergency Medicine | San Diego, CA | $7,203 | 15 |
| , DO | Neuromusculoskeletal Medicine & OMM | Blue Springs, MO | $6,968 | 22 |
| , MD | Infectious Disease | Louisville, KY | $6,674 | 8 |
| , MD | Infectious Disease | Thousands Oaks, CA | $6,357 | 8 |
| , MD | Infectious Disease | San Antonio, TX | $6,142 | 17 |
| , MD | Internal Medicine | Whitesburg, KY | $5,983 | 10 |
| , MD | Infectious Disease | Mission Viejo, CA | $5,919 | 15 |
| , MD | Internal Medicine | Baton Rouge, LA | $5,564 | 8 |
| , MD | Infectious Disease | Safety Harbor, FL | $5,452 | 14 |
| , MD | Emergency Medicine | Southfield, MI | $5,287 | 8 |
| , EDWARD HIRSCH MD | Infectious Disease | Tamarac, FL | $5,273 | 17 |
| , MD | Infectious Disease | Lafayette, CO | $4,859 | 11 |
| , MD | Internal Medicine | Ocala, FL | $4,817 | 6 |
| , MD | Specialist | Omaha, NE | $4,695 | 19 |
| , MD | Undersea and Hyperbaric Medicine | San Antonio, TX | $4,585 | 6 |
| , MD, FACP | Specialist | Tampa, FL | $3,839 | 7 |
Ad
Manufacturing Companies
- The Medicines Company $1.8M
- Melinta Therapeutics, Inc. $643,333
Product Information
- Type Drug
- Total Payments $2.4M
- Total Doctors 4,008
- Transactions 10,296
About ORBACTIV
ORBACTIV is a drug associated with $2.4M in payments to 4,008 healthcare providers, recorded across 10,296 transactions in the CMS Open Payments database. The primary manufacturer is The Medicines Company.
Payment data is available from 2017 to 2019. In 2019, $643,333 was paid across 49 transactions to 2 doctors.
The most common payment nature for ORBACTIV is "Unspecified" ($1.2M, 48.4% of total).
ORBACTIV is associated with 13 research studies, including "ML-ORI-102" ($576,221).